Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned a consensus rating of “Hold” from the ten research firms that are covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $10.78.

Several research firms have issued reports on ZNTL. UBS Group lowered Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $28.00 to $5.00 in a research note on Thursday, June 20th. Morgan Stanley reiterated an “equal weight” rating and set a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wells Fargo & Company lowered shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $29.00 to $9.00 in a report on Tuesday, June 18th. Finally, Stifel Nicolaus reduced their target price on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, June 18th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC increased its stake in shares of Zentalis Pharmaceuticals by 84.8% in the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after buying an additional 11,997 shares during the period. Algert Global LLC bought a new position in Zentalis Pharmaceuticals in the second quarter valued at about $78,000. Decheng Capital LLC increased its position in Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after purchasing an additional 970,859 shares during the period. Squarepoint Ops LLC raised its holdings in Zentalis Pharmaceuticals by 543.8% during the 2nd quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock worth $608,000 after purchasing an additional 125,649 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth about $402,000.

Zentalis Pharmaceuticals Stock Down 1.0 %

NASDAQ:ZNTL opened at $3.01 on Thursday. The firm has a market capitalization of $214.04 million, a PE ratio of -0.90 and a beta of 1.70. Zentalis Pharmaceuticals has a 12-month low of $2.83 and a 12-month high of $21.34. The firm has a 50-day moving average price of $3.39 and a 200 day moving average price of $7.38.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same period last year, the business earned ($1.85) earnings per share. On average, research analysts expect that Zentalis Pharmaceuticals will post -2.95 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.